Literature DB >> 31103387

Impact of Microbiological Organism Type on Surgically Managed Endocarditis.

Judson B Williams1, Asad A Shah2, Shuaiqi Zhang3, Sin-Ho Jung3, Babatunde Yerokun3, Sreekanth Vemulapalli3, Peter K Smith4, James S Gammie5, Jeffrey G Gaca6.   

Abstract

BACKGROUND: This study describes the impact of organism and valve type on surgically managed infective endocarditis (IE) from The Society of Thoracic Surgeons (STS) database. We developed a risk model for surgically managed endocarditis that includes the microbiological organism.
METHODS: The STS database was queried for adult patients with surgically managed endocarditis from July 1, 2011, to June 30, 2016. Outcomes were compared based on (1) causative microbiological organism, (2) valve type (native vs prosthetic), and (3) endocarditis on the right (tricuspid) vs left (mitral, aortic) sides. Univariate and risk adjusted models were developed with odds ratios for mortality for each organism type referenced against Streptococcus.
RESULTS: The study population included 21,388 operations (93%) for left-sided IE and 1698 (7%) for right-sided IE. Streptococcus (28%) and Staphylococcus (27%) were the most common infecting organisms, followed by Enterococcus (11%). After multivariate adjustment, microbiological organism type was significantly associated with operative mortality for patients with left-sided endocarditis, with an adjusted odds ratio of 2.9 for fungal, 1.4 for Staphylococcus, and 1.3 for culture-negative vs Streptococcus. For right-sided endocarditis, there were no differences in outcomes by organism type. Left-sided prosthetic valve endocarditis had a higher operative mortality than left-sided native valve endocarditis (12% vs 8%, P < .001). In contrast, surgery for right-sided endocarditis carried lower operative mortality, with no mortality difference between prosthetic valve endocarditis and native valve endocarditis (5% vs 4%, P = .6).
CONCLUSIONS: Organism type influences the operative mortality for left-sided endocarditis. Surgery for left-sided and prosthetic valve endocarditis is associated with higher operative mortality. Risk adjustment for operative outcomes in endocarditis may need to account for microbiological organism type.
Copyright © 2019 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 31103387     DOI: 10.1016/j.athoracsur.2019.04.025

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

1.  Should we include microorganisms in scores to predict outcome in candidates for cardiac surgery during the acute phase of endocarditis?

Authors:  Pierre Tattevin; Pierre Fillâtre; Serge Tchamgoué; Mathieu Lesouhaitier; Nicolas Nesseler; Jean-Marc Tadié
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

2.  Bugs at the operating theatre in infective endocarditis: one step forward, still a long way to go.

Authors:  Juan M Pericàs; Eduard Quintana; José M Miró
Journal:  J Thorac Dis       Date:  2019-10       Impact factor: 2.895

3.  The Evolving Burden of Drug Use Associated Infective Endocarditis in the United States.

Authors:  Arnar Geirsson; Asher Schranz; Oliver Jawitz; Makoto Mori; Liqi Feng; Brittany A Zwischenberger; Alexander Iribarne; Joseph Dearani; Gregory Rushing; Vinay Badhwar; Juan A Crestanello
Journal:  Ann Thorac Surg       Date:  2020-05-06       Impact factor: 4.330

4.  Surgical Procedure Time and Mortality in Patients with Infective Endocarditis Caused by Staphylococcus aureus or Streptococcus Species.

Authors:  Gregor Paul; Laurin Ochs; Christopher Hohmann; Stephan Baldus; Guido Michels; Charlotte Meyer-Schwickerath; Gerd Fätkenheuer; Navid Mader; Thorsten Wahlers; Carolyn Weber; Norma Jung
Journal:  J Clin Med       Date:  2022-04-30       Impact factor: 4.964

5.  Characteristics of infective endocarditis in a cancer population.

Authors:  Cullen Grable; Syed W Yusuf; Juhee Song; George M Viola; Owais Ulhaq; Jose Banchs; Corey T Jensen; Harsh Goel; Saamir A Hassan
Journal:  Open Heart       Date:  2021-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.